Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Observational 1

Sponsor

Conditions

Diabetes Mellitus, Type 2 1

Interventions

Paclitaxel 489Carboplatin 435Gemcitabine 394Docetaxel 385Cisplatin 359pembrolizumab 343Bevacizumab 335Nivolumab 261Pemetrexed 242Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 91

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × INDUSTRY × Dipeptidyl-Peptidase IV Inhibitors × Clear all
NCT03464045 2025-04-20

Empa PASS on Urinary Tract Malignancies

Boehringer Ingelheim

Completed
344,995 enrolled 12 charts

Diabetes Mellitus, Type 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡